SLC25A24
protein-codingsolute carrier family 25 member 24, the group of Solute carrier family 25|EF-hand domain containing
Gene summary
This gene encodes a carrier protein that transports ATP-Mg exchanging it for phosphate. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~66.8 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012853
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0012853
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0012853
Submitter: ClinGen
SLC25A24 is located in chromosome 1 at 1p13.3 and encodes the solute carrier family 25 (Mitochondrial Carrier, Phosphate Carrier), member 24. Multiple disease entities have been reported in association with this gene. According to criteria outlined by the ClinGen Lumping and Splitting Working Group, there was no evidence of differences in their molecular mechanism and phenotypic spectrum. Therefore, the following disease entities have been lumped into one disease entity (MONDO:0012853): Gorlin-Chaudhry-Moss syndrome, Fontaine–Farriaux syndrome (FFS), and Fontaine progeroid syndrome. Petty–Laxova–Wiedemann syndrome was not included in this entity due to lack of molecular diagnosis (PMIDs: 2309786,19725131, 20583180). SLC25A24 was first reported in connection with SLC25A24-related Fontaine Progeroid syndrome in 2017 (PMID: 29100093; Ehmke et al. 2017). Fifteen probands across seven publications have been included in this curation (PMIDs: 38980211; 32732226; 31231135; 31775791; 30329211; 29100094; 29100093). Pathogenic SLC25A24 variants are missense and de novo, consisting of p.Arg217His (more frequent) or p.Arg217Cys. The mechanism of disease is gain-of-function where both p.Arg217Cys and p.Arg217His narrow the substrate cavity of the protein and disrupt transporter dynamics, leading to impaired mitochondrial ATP synthesis, increased mitochondrial membrane potential (hyperpolarization), and increased proton leak (PMID: 38980211). This gene-disease relationship is also supported by functional alteration assays, biochemical evidence, and a mouse model (PMIDs: 28350015; 25599384; 29100094; 29100093). In summary, there is definitive evidence supporting the relationship between SLC25A24 and autosomal dominant SLC25A24-related Fontaine Progeroid syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the Craniofacial Malformations Gene Curation Expert Panel on the meeting date 09/18/2025 (SOP Version 11).
Inheritance Pattern: AD
Disease ID:MONDO:0012853
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0012853
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Dermatologic; Genitourinary; Musculoskeletal
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SLC25A24 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_013386.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 22 | 4 | 27 | ||
| missense | 1 | 2 | 112 | 11 | 3 | 129 |
| nonsense | 4 | 2 | 6 | |||
| start loss | 1 | 1 | ||||
| frameshift | 3 | 3 | 6 | |||
| splice donor/acceptor (+/-2bp) | 4 | 4 | ||||
| Total | 1 | 2 | 125 | 38 | 7 | 173 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_037518.3 | 10 | MANE Select | |
| Ensembl | ENSP00000457733.1 | 10 | MANE Select | |
| RefSeq | NP_998816.1 | 10 | Standard | |
| Ensembl | ENSP00000264128.9 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- miR-targeted genes in epithelium - TarBase
- miR-targeted genes in lymphocytes - TarBase
- miR-targeted genes in muscle cell - TarBase
Biological Process
- mitochondrial transport
- regulation of cell death
- ATP transport
- cellular response to oxidative stress
- transmembrane transport
Molecular Function
- ATP transmembrane transporter activity
- calcium ion binding
Cellular Component
- mitochondrion
- mitochondrial inner membrane
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000565488
- Coding exons
- 10
- Length
- 66814
- Individuals with no LoFs
- 125537
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 211
- Defined
- 125748
- p
- 0.000839
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.824 | 220 | 257 | 0.855 | 0.0000125 | 3109 |
| Missense (PolyPhen) | 65 | 94.035 | 0.69123 | 1186 | ||
| Synonymous | -0.663 | 99 | 91.0 | 1.09 | 0.00000462 | 901 |
| Loss of Function | 1.05 | 21 | 26.9 | 0.782 | 0.00000144 | 302 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.0012 | 0.0012 | notable |
| Latino/Admixed American | 0.00026 | 0.00026 | rare |
| Ashkenazi Jewish | 0.0028 | 0.0027 | notable |
| East Asian | 0.0017 | 0.0017 | notable |
| Finnish | 0.0011 | 0.0011 | notable |
| European (Non-Finnish) | 0.00055 | 0.00055 | rare |
| South Asian | 0.00092 | 0.00091 | rare |
| Other | 0.0018 | 0.0018 | notable |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Calcium-dependent mitochondrial solute carrier. Mediates the reversible, electroneutral exchange of Mg-ATP or Mg-ADP against phosphate ions, catalyzing the net uptake or efflux of adenine nucleotides across the mitochondrial inner membrane. Nucleotide transport is inactive when cytosolic calcium levels are low, and is activated by an increase in cytosolic calcium levels. May play a role in protecting cells against oxidative stress- induced cell death, probably by promoting the formation of calcium-phosphate precipitates in the mitochondrial matrix, and thereby buffering calcium levels in the mitochondrial matrix. {ECO:0000269|PubMed:15123600, ECO:0000269|PubMed:22015608, ECO:0000269|PubMed:29100093}.;
- Disease
- DISEASE: Fontaine progeroid syndrome (FPS) [MIM:612289]: An autosomal dominant progeroid disorder characterized by prenatal and postnatal growth retardation, decreased subcutaneous fat tissue, wrinkled skin, an aged appearance since birth, an abnormal scalp hair pattern, sparse hair, hypoplastic distal phalanges with hypoplastic nails, a widely open anterior fontanel, facial dysmorphisms, and craniosynostosis. Early death is observed in some patients. {ECO:0000269|PubMed:29100093}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.114
Intolerance Scores
- LoFtool
- 0.876
- RVIS EVS
- -0.71
- RVIS percentile EVS
- 14.57
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.248
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |